Are there instances where you would use C5 complement inhibitors for isolated elevation of sc5b-9 in the absence of other TA-TMA features?   

A recent prospective open-label prospective trial, enrolling 21 patients, by Jodele et al., PMID 37946262, published in Blood March 2024, used elevation in sc5b-9 as well as proteinuria as eligibility for the start of therapy with a C5 blocker. They suggest that early treatment of TA-TMA may be of b...